As of January 2023, briquilimab, the company's lead product, had a demonstrated efficacy and safety profile in over 130 dosed subjects and healthy volunteers, with clinical outcomes as a conditioning agent in SCID, acute myeloid leukemia (AML), MDS, FA, and SCD. In addition, briquilimab is being advanced as a transformational non-genotoxic conditioning agent for gene therapy.

In Janaury 2023, the company went public with gross proceeds from the offering totally approximately $103.5 million.